Hubei Guangji Pharmaceutical Co., Ltd. (SHE:000952)
5.36
-0.07 (-1.29%)
Nov 18, 2026, 3:04 PM CST
SHE:000952 Revenue
Hubei Guangji Pharmaceutical had revenue of 123.49M CNY in the quarter ending September 30, 2026, a decrease of -14.78%. This brings the company's total for the last twelve months to 630.16M, up 4.01% year-over-year. In the year 2025, Hubei Guangji Pharmaceutical had annual revenue of 623.97M, down -2.32%. That makes Hubei Guangji Pharmaceutical the 23,153rd largest company in the world by revenue and 4,184th in China.
Revenue (ttm)
630.16M
Revenue Growth
+4.01%
P/S Ratio
2.92
Revenue / Employee
541.37K
Employees
1,164
Market Cap
1.84B
Revenue by Geography
- domestic 404.97M 64.9%
- Foreign 219.00M 35.1%
Fiscal year ended Dec 31, 2025 See the full SHE:000952 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 623.97M | -14.83M | -2.32% |
| Dec 31, 2024 | 638.80M | -99.02M | -13.42% |
| Dec 31, 2023 | 737.82M | -59.82M | -7.50% |
| Jan 1, 2023 | 797.64M | 12.07M | 1.54% |
| Jan 1, 2022 | 785.57M | 97.40M | 14.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Int'l Group | 34.69B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.80B |
| Zhejiang Zhenyuan Share | 1.79B |
| GuangYuYuan Chinese Herbal Medicine | 1.31B |
| Hangzhou Minsheng Healthcare | 902.62M |
| Hangzhou Bio-Sincerity Pharma-Tech | 617.95M |
| Aurora Optoelectronics | 604.05M |
| Shandong Keyuan Pharmaceutical | 578.07M |